Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torisel in unresectable HCC
NCT01251458Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2009
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in hepatocellular carcinoma (HCC), sponsored by The Chinese University of Hong Kong. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Oct 2009; status: completed.
02
Drugs
temsirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01251458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251458.